Medical Condition News

RSS

NutraGene introduces first ever commercial type 2 diabetes genetic test

With the launch of the country's first ever commercial genetic test for type 2 diabetes, Indians will now have access to clinically relevant and cost effective genetic risk assessment services. NutraGene, a Delhi based genomics company that launched the tests believes that its type 2 diabetes genetic test will provide physicians an effective tool in assessing the risk of diabetes in the Indian population and will help in implementing personalized prevention and management strategies.

3 Apr 2012

Meda opens China affiliate based in Beijing

Meda has established an affiliate in Hong Kong. At the end of last year, Meda opened its China affiliate based in Beijing. Meda will begin by commercializing two of its well-established products in Hong Kong; Elidel for the treatment of atopic dermatitis (eczema) and azelastine for the treatment of allergic rhinitis.

3 Apr 2012

Combination treatment effective against melanoma

Research from The Cancer Institute of New Jersey (CINJ) shows that a coordinated effort to block signaling pathways that promote cancer cell growth and survival enhances programmed cell death in melanoma.

3 Apr 2012

Expensive robotic-assisted bladder cancer surgery results in fewer deaths, in-patient complications

With technological advancements opening the door to less invasive medical procedures, robotic-assisted surgery is becoming increasingly popular, despite being more expensive than traditional surgery. Robotic-assisted surgical removal of the bladder due to cancer is a new approach to the traditional "open" - or more invasive - operation called a radical cystectomy.

3 Apr 2012

New data demonstrates anti-cancer activities of Oncoprex

New data demonstrating the anti-cancer activities of Oncoprex were presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, IL. The study, "Synergistic antitumor activity of AKT inhibitor MK2206 and FUS1 nanoparticles in LKB1 mutant NSCLC" (Meng J, Lara-Guerra H, Ji L, Roth JA) is authored by a team of investigators from The University of Texas MD Anderson Cancer Center.

3 Apr 2012

Transgenic mice to visualize metastasis and inflammation

One of the major routes of tumor cell dissemination to form metastasis at distant organs in the body is the lymphatic system. To study this process, still poorly understood, and to gain information on which tumors prefer this route for dissemination and how to block it, researchers of the Spanish National Cancer Research Center, led by researcher Sagrario Ortega, have created transgenic mice in which, for the first time, the growth of the lymphatic vessels can be visualized in the whole animal, by a light-emitting reaction, as tumor progresses and forms metastasis.

3 Apr 2012

UCD develops Adult Dose-Risk Smartcard

According to a study in the April issue of the Journal of the American College of Radiology, the department of radiology at the University of Colorado in Denver has developed a convenient, pocket-sized reference card to communicate the effective doses and radiation risks of common adult radiologic exams to referring physicians and patients.

3 Apr 2012

UCB receives FDA approval for Neupro to treat idiopathic Parkinson's, RLS

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro (Rotigotine Transdermal System) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease (PD) and as a treatment for moderate-to-severe primary Restless Legs Syndrome.

3 Apr 2012

ACOEM joins AHA, ALA and other organizations to formally oppose S.J. Res. 37

The American College of Occupational and Environmental Medicine (ACOEM) has joined the American Heart Association, the American Lung Association, and other leading organizations to formally oppose S.J. Res. 37, a resolution by Senator James Inhofe (R-Okla) that employs the Congressional Review Act to reverse the U.S. Environmental Protection Agency's (EPA) Mercury and Air Toxics Standards for Power Plants.

3 Apr 2012

Avedro, ACOS commence accelerated corneal cross-linking Phase 3 study

ACOS and Avedro, Inc. jointly announced today the initiation of a Phase 3, multi-center, randomized, controlled evaluation to study accelerated corneal collagen cross-linking in eyes with keratoconus or corneal ectasia after refractive surgery.

3 Apr 2012

PET allows survival predictions in sarcoma after initial cycle of neoadjuvant chemo

An early Positron Emission Tomography (PET) response after the initial cycle of neoadjuvant chemotherapy can be used to predict increased survival in patients with soft tissue sarcomas, according to a study by researchers with UCLA's Jonsson Comprehensive Cancer Center.

3 Apr 2012

MMRF announces unique oncology research partnership

The Multiple Myeloma Research Foundation (MMRF) today announced a unique oncology research partnership. This multi-year agreement involves several partners including the Translational Genomics Research Institute (TGen), Spectrum Health, and the Van Andel Research Institute.

3 Apr 2012

Patients prefer immediate access to radiology reports

You've been experiencing severe back pain and weakness in your right leg. Your doctor orders a spinal MRI to help determine the cause. The radiology report diagnoses cancer. Would you rather read the detailed medical report right away at home or wait until your doctor was available to explain the test results, diagnosis and treatment options? This scenario was part of a study at Wake Forest Baptist Medical Center designed to determine if patients wanted online access to radiology test results and, if so, how quickly.

3 Apr 2012

Detailed information on how metastasin protein facilitates spread of tumour cells

Researchers from the Department of Chemistry and Molecular Biology at the University of Gothenburg have managed for the first time to obtain detailed information about the role of the protein metastasin in the spread of tumour cells.

3 Apr 2012

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

ARIAD Pharmaceuticals, Inc. today announced the presentation of new preclinical data on its investigational pan-BCR-ABL inhibitor, ponatinib, and its investigational dual EGFR-ALK inhibitor, AP26113, at the American Association for Cancer Research Annual Meeting in Chicago.

3 Apr 2012

Cell graphs link structure of human tissue to corresponding biological function

Computer scientists and biologists in the Data Science Research Center at Rensselaer Polytechnic Institute have developed a rare collaboration between the two very different fields to pick apart a fundamental roadblock to progress in modern medicine. Their unique partnership has uncovered a new computational model called "cell graphs" that links the structure of human tissue to its corresponding biological function.

3 Apr 2012

Systemic inflammation may contribute to depressive symptoms

New research published in the April issue of The Journal of Nuclear Medicine reveals that systemic inflammation causes an increase in depressive symptoms and metabolic changes in the parts of the brain responsible for mood and motivation. With this finding, researchers can begin to test potential treatments for depression for patients that experience symptoms that are related to inflammation in the body or within the brain.

3 Apr 2012

Only few cancer patients are referred to orthopedic services

There is a disconnect between the number of cancer patients estimated to have bone metastases and the number of patients who are sent for orthopedic care each year, states an article in the Canadian Journal of Surgery (CJS).

3 Apr 2012

Keryx does not meet primary endpoint in perifosine + capecitabine Phase 3 trial for colorectal cancer

Keryx Biopharmaceuticals, Inc. reported today that the Phase 3 "X-PECT" clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.

3 Apr 2012

New research: ADHD is more than one disorder

According to new research conducted at Oregon Health & Science University, Attention Deficit Hyperactivity Disorder (ADHD) is more than one disorder. It's an entire family of disorders, much like the multiple subtypes of cancer.

3 Apr 2012